COVID-19 Vaccine Candidate: Moderna announces 94.5% efficacy in Phase 3 trial
by Press Release from Outbreak News Today on (#5AEF0)
By NewsDesk @bactiman63 Cambridge, MA biotechnology company, Moderna, Inc. announced today that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known [...]
The post COVID-19 Vaccine Candidate: Moderna announces 94.5% efficacy in Phase 3 trial appeared first on Outbreak News Today.